From single drug targets to synergistic network pharmacology in ischemic stroke
Ana I Casas, Ahmed A Hassan, Simon J Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W M Kleikers, Emre Guney, Javier Egea, Manuela G López, Jan Baumbach, Harald H H W Schmidt, Ana I Casas, Ahmed A Hassan, Simon J Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W M Kleikers, Emre Guney, Javier Egea, Manuela G López, Jan Baumbach, Harald H H W Schmidt
Abstract
Drug discovery faces an efficacy crisis to which ineffective mainly single-target and symptom-based rather than mechanistic approaches have contributed. We here explore a mechanism-based disease definition for network pharmacology. Beginning with a primary causal target, we extend this to a second using guilt-by-association analysis. We then validate our prediction and explore synergy using both cellular in vitro and mouse in vivo models. As a disease model we chose ischemic stroke, one of the highest unmet medical need indications in medicine, and reactive oxygen species forming NADPH oxidase type 4 (Nox4) as a primary causal therapeutic target. For network analysis, we use classical protein-protein interactions but also metabolite-dependent interactions. Based on this protein-metabolite network, we conduct a gene ontology-based semantic similarity ranking to find suitable synergistic cotargets for network pharmacology. We identify the nitric oxide synthase (Nos1 to 3) gene family as the closest target to Nox4 Indeed, when combining a NOS and a NOX inhibitor at subthreshold concentrations, we observe pharmacological synergy as evidenced by reduced cell death, reduced infarct size, stabilized blood-brain barrier, reduced reoxygenation-induced leakage, and preserved neuromotor function, all in a supraadditive manner. Thus, protein-metabolite network analysis, for example guilt by association, can predict and pair synergistic mechanistic disease targets for systems medicine-driven network pharmacology. Such approaches may in the future reduce the risk of failure in single-target and symptom-based drug discovery and therapy.
Keywords: NOX4; network analysis; network pharmacology; stroke.
Conflict of interest statement
Conflict of interest statement: H.H.H.W.S. is a cofounder of a biotech company, Vasopharm, engaged in the development of small-molecule NOS inhibitors, currently in stage III clinical development. However, H.H.H.W.S. has no operative role in the company and holds less than 1% of shares.
Copyright © 2019 the Author(s). Published by PNAS.
Figures
References
- Yildirim MA, Goh K-I, Cusick ME, Barabási A-L, Vidal M. Drug-target network. Nat Biotechnol. 2007;25:1119–1126.
- Aguirre-Plans J, et al. Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology. Pharmaceuticals (Basel) 2018;11:E61.
- Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25:1110–1111.
- Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.
- Menche J, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347:1257601.
- Langhauser F, et al. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. NPJ Syst Biol Appl. 2018;4:8.
- Barabási A-L, Oltvai ZN. Network biology: Understanding the cell’s functional organization. Nat Rev Genet. 2004;5:101–113.
- Batra R, et al. On the performance of de novo pathway enrichment. NPJ Syst Biol Appl. 2017;3:6.
- Alcaraz N, et al. De novo pathway-based biomarker identification. Nucleic Acids Res. 2017;45:e151.
- Koduru P, Chaganti R. Congenital chromosome breakage clusters within Giemsa-light bands and identifies sites of chromatin instability. Cytogenet Cell Genet. 1988;49:269–274.
- Li X, et al. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. Artif Intell Med. 2017;83:35–43.
- Meladze VG. [Temporal characteristics of the autoregulation process of local cerebral blood flow in hypo- and hypertension] Patol Fiziol Eksp Ter. 1985:29–32. Russian.
- Vitali F, Mulas F, Marini P, Bellazzi R. Network-based target ranking for polypharmacological therapies. J Biomed Inform. 2013;46:876–881.
- Chua HE, Bhowmick SS, Tucker-Kellogg L. Synergistic target combination prediction from curated signaling networks: Machine learning meets systems biology and pharmacology. Methods. 2017;129:60–80.
- Vilar S, Hripcsak G. The role of drug profiles as similarity metrics: Applications to repurposing, adverse effects detection and drug-drug interactions. Brief Bioinform. 2017;18:670–681.
- Guney E. Reproducible drug repurposing: When similarity does not suffice. Pac Symp Biocomput. 2017;22:132–143.
- Casas AI, et al. NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage. Proc Natl Acad Sci USA. 2017;114:12315–12320.
- Kleinschnitz C, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol. 2010;8:e1000479.
- Li F, Xu W, Zhao S. Regulatory roles of metabolites in cell signaling networks. J Genet Genomics. 2013;40:367–374.
- Nisimoto Y, Diebold BA, Cosentino-Gomes D, Lambeth JD. Nox4: A hydrogen peroxide-generating oxygen sensor. Biochemistry. 2014;53:5111–5120, and erratum (2014) 53:5472.
- Piovesan D, Giollo M, Ferrari C, Tosatto SCE. Protein function prediction using guilty by association from interaction networks. Amino Acids. 2015;47:2583–2592.
- Pesquita C, et al. Metrics for GO based protein semantic similarity: A systematic evaluation. BMC Bioinformatics. 2008;9(Suppl 5):S4.
- Wang JZ, Du Z, Payattakool R, Yu PS, Chen C-F. A new method to measure the semantic similarity of GO terms. Bioinformatics. 2007;23:1274–1281.
- Kleikers PWM, et al. A combined pre-clinical meta-analysis and randomized confirmatory trial approach to improve data validity for therapeutic target validation. Sci Rep. 2015;5:13428.
- O’Collins VE, et al. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467–477.
- Peña ID, Borlongan C, Shen G, Davis W. Strategies to extend thrombolytic time window for ischemic stroke treatment: An unmet clinical need. J Stroke. 2017;19:50–60.
- Chen R-L, Balami JS, Esiri MM, Chen L-K, Buchan AM. Ischemic stroke in the elderly: An overview of evidence. Nat Rev Neurol. 2010;6:256–265.
- Lehner C, et al. Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases. Antioxid Redox Signal. 2011;15:1305–1323.
- Enciu A-M, Gherghiceanu M, Popescu BO. Triggers and effectors of oxidative stress at blood-brain barrier level: Relevance for brain ageing and neurodegeneration. Oxid Med Cell Longev. 2013;2013:297512.
- Zhao X-M, et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol. 2011;7:e1002323.
- Huang L, et al. DrugComboRanker: Drug combination discovery based on target network analysis. Bioinformatics. 2014;30:i228–i236.
- Vidal M, Cusick ME, Barabási A-L. Interactome networks and human disease. Cell. 2011;144:986–998.
- Futschik ME, Chaurasia G, Herzel H. Comparison of human protein-protein interaction maps. Bioinformatics. 2007;23:605–611.
- Lehne B, Schlitt T. Protein-protein interaction databases: Keeping up with growing interactomes. Hum Genomics. 2009;3:291–297.
- Rolland T, et al. A proteome-scale map of the human interactome network. Cell. 2014;159:1212–1226.
- Mehta V, Trinkle-Mulcahy L. Recent advances in large-scale protein interactome mapping. F1000 Res. 2016;5:782.
- Amaral LAN. A truer measure of our ignorance. Proc Natl Acad Sci USA. 2008;105:6795–6796.
- Altenhöfer S, Radermacher KA, Kleikers PWM, Wingler K, Schmidt HHHW. Evolution of NADPH oxidase inhibitors: Selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2015;23:406–427.
- Miettinen TP, Björklund M. NQO2 is a reactive oxygen species generating off-target for acetaminophen. Mol Pharm. 2014;11:4395–4404.
- Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc Natl Acad Sci USA. 2018;115:5839–5848.
- Geiszt M. NADPH oxidases: New kids on the block. Cardiovasc Res. 2006;71:289–299.
- Espey MG, et al. A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Ann N Y Acad Sci. 2002;962:195–206.
- Ghezzi P, Jaquet V, Marcucci F, Schmidt HHHW. The oxidative stress theory of disease: Levels of evidence and epistemological aspects. Br J Pharmacol. 2017;174:1784–1796.
- Kleinschnitz C, et al. NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. J Cereb Blood Flow Metab. 2016;36:1508–1512.
- Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci. 2004;27:283–289.
- Niwa M, et al. Time course of expression of three nitric oxide synthase isoforms after transient middle cerebral artery occlusion in rats. Neurol Med Chir (Tokyo) 2001;41:63–73.
- Dao VT-V, et al. Pharmacology and clinical drug candidates in redox medicine. Antioxid Redox Signal. 2015;23:1113–1129.
- Sun Q-A, Hess DT, Wang B, Miyagi M, Stamler JS. Off-target thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870) Free Radic Biol Med. 2012;52:1897–1902.
- Ott C, et al. Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers. Br J Clin Pharmacol. January 21, 2019 doi: 10.1111/bcp.13870.
- Mistry RK, et al. Transcriptional regulation of cystathionine-γ-lyase in endothelial cells by NADPH oxidase 4-dependent signaling. J Biol Chem. 2016;291:1774–1788.
- Chan SJ, et al. Cystathionine β-synthase inhibition is a potential therapeutic approach to treatment of ischemic injury. ASN Neuro. 2015;7:1759091415578711.
- Noronha-Dutra AA, Epperlein MM, Woolf N. Reaction of nitric oxide with hydrogen peroxide to produce potentially cytotoxic singlet oxygen as a model for nitric oxide-mediated killing. FEBS Lett. 1993;321:59–62.
- Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol. 2008;4:682–690.
- Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: From computational models to experimental design principles. Curr Pharm Des. 2014;20:23–36.
Source: PubMed